Engineered Liposomes for Potential
-Particle Therapy of Metastatic Cancer
Stavroula Sofou, PhD1,2,
James L. Thomas, PhD3,
Hung-yin Lin, PhD3,
Michael R. McDevitt, PhD2,
David A. Scheinberg, MD, PhD2 and
George Sgouros, PhD4
1 Department of Medical Physics, Memorial Sloan-Kettering Cancer Center, New York, New York
2 Department of Molecular Pharmacology and Chemistry, Memorial Sloan-Kettering Cancer Center, New York, New York
3 Department of Chemical Engineering, Columbia University, New York, New York
4 Division of Nuclear Medicine, Department of Radiology, Johns Hopkins Medicine, Baltimore, Maryland

View larger version (20K):
[in a new window]
|
FIGURE 1. Simplified 225Ac decay cascade with associated particulate decays and half-lives.
|
|

View larger version (76K):
[in a new window]
|
FIGURE 2. Negative-staining transmission electron microscopy images of liposomes prepared with 800-nm (A) and 100-nm (B) filter diameter.
|
|

View larger version (17K):
[in a new window]
|
FIGURE 5. Theoretical predictions of 213Bi retention for different liposome sizes (solid line). Radionuclides were assumed to be uniformly entrapped into the liposomal aqueous compartment. The average recoil distance of 87.6 nm was used for all -emitting intermediates to simplify calculations. Binding of radionuclides to the liposomal membrane will significantly reduce retention (dotted line).
|
|
Copyright © 2004 by the Society of Nuclear Medicine.